logo
logo

Bolt Biotherapeutics Closes $93.5 Million Series C Financing

Jul 01, 2020•about 5 years ago

Amount Raised

$93 Million

Round Type

series c

Redwood City

Description

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company developing its Immune-Stimulating Antibody Conjugate (ISAC) platform technology to harness the power of the innate immune system to treat cancer, today announced the closing of an oversubscribed $93.5 million Series C financing. Led by Sofinnova Investments, the Series C financing included participation from new investors RA Capital Management, Surveyor Capital (a Citadel Company), Rock Springs Capital, Samsara BioCapital and Pfizer Ventures as well as existing investors Novo Holdings, Vivo Capital, Pivotal bioVenture Partners and others.

Company Information

Company

Bolt Biotherapeutics' Immune Stimulating Antibody Conjugate (Isac) Platform Technology

Location

Redwood City, California, United States

About

The Boltbody™ platform consists of Immune-Stimulating Antibody Conjugates (ISAC) that harness the ability of innate immune stimulants to convert cold tumors into immunologically hot tumors, thereby illuminating tumors to the immune system and allowing them to be invaded by tumor-killing cells. Boltbody™ ISACs have demonstrated the ability to eliminate tumors following systemic administration in preclinical models and have also led to the development of immunological memory, which is predicted to translate into more durable clinical responses for patients. The company's first Boltbody™ to enter clinical development, BDC-1001, is currently being evaluated in patients with HER2-expressing solid tumors.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech